Resource Summary Report

Generated by dkNET on Sep 4, 2026

TOV-112D

RRID:CVCL_3612
Type: Cell Line

Proper Citation

RRID:CVCL_3612

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3612

Proper Citation: RRID:CVCL_3612

Description: Cell line TOV-112D is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian endometrioid adenocarcinoma

Defining Citation: PMID:10949993, PMID:11641787, PMID:16380993, PMID:18507860, PMID:19058220, PMID:19288585, PMID:20204287, PMID:22328975, PMID:22460905, PMID:22710073, PMID:22931248, PMID:24023729, PMID:25230021, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26589293, PMID:27235858, PMID:27397505, PMID:27561551, PMID:28196595, PMID:30485824, PMID:30894373, PMID:30971826, PMID:31068700, PMID:33328126, PMID:35839778

Comments: Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TOV-112D

Synonyms: TOV-112d, TOV112D, TOV-112, TOV112

Cross References: BTO:BTO_0005182, CLO:CLO_0009384, EFO:EFO_0005263, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-3593, ATCC:CRL-11731, BCRC:60408, BioGRID_ORCS_Cell_line:201,

BioSample:SAMN03471348, BioSample:SAMN10988342, cancercelllines:CVCL_3612, CancerTools:161766, Cell_Model_Passport:SIDM01170, ChEMBL-Cells:CHEMBL3707165, ChEMBL-Targets:CHEMBL3707166, Cosmic:875292, Cosmic:1066219, Cosmic:1102818, Cosmic:1113278, Cosmic:1139220, Cosmic:1305335, Cosmic:1709264, Cosmic:2186587, Cosmic-CLP:1299070, DepMap:ACH-000048, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1299070, GEO:GSE35972, GEO:GSM274697, GEO:GSM289383, GEO:GSM289384, GEO:GSM289387, GEO:GSM289388, GEO:GSM313690, GEO:GSM659407, GEO:GSM711721, GEO:GSM784575, GEO:GSM851944, GEO:GSM887710, GEO:GSM888803, GEO:GSM1001425, GEO:GSM1001426, GEO:GSM1001489, GEO:GSM1291152, GEO:GSM1340594, GEO:GSM1341134, GEO:GSM1374964, GEO:GSM1670546, IARC_TP53:20197, LiGeA:CCLE_580, LINCS_LDP:LCL-1920, PharmacoDB:TOV112D_1604_2019, PRIDE:PXD003668, PRIDE:PXD030304, Progenetix:CVCL_3612, PubChem_Cell_line:CVCL_3612, Wikidata:Q54972795

ID: CVCL_3612

Record Creation Time: 20220427T221632+0000

Record Last Update: 20260904T015830+0000

Ratings and Alerts

No rating or validation information has been found for TOV-112D.

No alerts have been found for TOV-112D.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Tong J, et al. (2026) p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer. Redox biology, 90, 104043.

Yang L, et al. (2026) Trichostatin Analogues From the Karst Cave Associated Streptomyces sp. DX6D14. Chemistry & biodiversity, 23(5), e71334.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. Advanced biology, 10(3), e00404.

Min Y, et al. (2026) The USP19-DnaJC7 Axis Stabilizes p53 in Cisplatin-Treated Epithelial Ovarian Cancer. Cells, 15(10).

Kimmel GJ, et al. (2026) Universal principles of cell population growth follow from local contact inhibition. iScience, 29(6), 115953.

Wang M, et al. (2025) Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer. Open medicine (Warsaw, Poland), 20(1), 20251266.

Wang K, et al. (2025) Molecular mechanisms of CAND2 in regulating SCF ubiquitin ligases. Nature communications, 16(1), 1998.

Iimori Y, et al. (2025) SLFN11-mediated tRNA regulation induces cell death by disrupting proteostasis in response to DNA-damaging agents. Nucleic acids research, 53(15).

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. Cancer research communications, 5(1), 24.

Iimori Y, et al. (2025) SLFN11-mediated tRNA regulation induces cell death by disrupting proteostasis in response to DNA-damaging agents. bioRxiv : the preprint server for biology.

Onji H, et al. (2024) Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks. Oncogene, 43(32), 2475.

Kofink C, et al. (2022) A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nature communications, 13(1), 5969.

Yamamoto TM, et al. (2022) Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. Molecular cancer therapeutics, 21(4), 647.

Altintas DM, et al. (2022) The PSI Domain of the MET Oncogene Encodes a Functional Disulfide Isomerase Essential for the Maturation of the Receptor Precursor. International journal of molecular sciences, 23(20).

Faucher-Giguère L, et al. (2022) High-grade ovarian cancer associated H/ACA snoRNAs promote cancer cell proliferation and survival. NAR cancer, 4(1), zcab050.

Cumin C, et al. (2022) Glycosphingolipids are mediators of cancer plasticity through independent signaling pathways. Cell reports, 40(7), 111181.

Li Y, et al. (2021) Down-regulation of PSMD4 can attenuate autophagy, enhance the accumulation of intracellular ROS, and increase the sensitivity of epithelial ovarian cancer to carboplatin by inhibiting the NF-?B pathway. Translational cancer research, 10(11), 4756.

Dorrigiv D, et al. (2021) Microdissected Tissue vs Tissue Slices-A Comparative Study of Tumor Explant Models Cultured On-Chip and Off-Chip. Cancers, 13(16).

Karnezis AN, et al. (2021) Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. Gynecologic oncology, 160(2), 568.

Huang YL, et al. (2020) Collagen-rich omentum is a premetastatic niche for integrin ?2-mediated peritoneal metastasis. eLife, 9.